<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088800</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01-06</org_study_id>
    <nct_id>NCT03088800</nct_id>
  </id_info>
  <brief_title>IBUPAP Study for Pain Management in Children</brief_title>
  <official_title>IBUPAP - Combination of Oral Ibuprofen and Acetaminophen (APAP) is Superior to Either Analgesic Alone for Pediatric Emergency Department (ED) Patients With Acute Mild to Moderate Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current literature supports ibuprofen and APAP are the most commonly used analgesics in the
      pediatric ED for acute mild to moderate traumatic/non-traumatic pain. However, the analgesic
      benefits of combination ibuprofen and APAP in this specific setting does not exist, but
      instead only as it applies to pediatric patients with postoperative pain. Thus, we have
      designed a double-blind, randomized, controlled clinical trial to evaluate analgesic
      efficacy, safety and feasibility of combination therapy to potentially broaden its clinical
      application in the pediatric ED. The investigators' hypothesize that combination oral
      ibuprofen and APAP therapy is superior to either drug alone and is an excellent analgesic
      modality for controlling acute mild to moderate traumatic/non-traumatic pain in the pediatric
      ED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' hypothesize the combination of oral ibuprofen and acetaminophen (APAP) is
      superior to either analgesic alone plus placebo for pediatric emergency department patients
      with acute mild to moderate traumatic/non-traumatic pain

        1. Intent to Treat, prospective, randomized, double-blind trial.

        2. Primary outcome: Pain reduction via NRS/FACES pain scale at times 0 and 60 minutes from
           administration of medication(s).

           Secondary outcomes: Antipyretic effects, level of analgesia achieved with each patient
           diagnosis(es), incidence and type of adverse effect(s), and patients' and parents'
           satisfaction with achieved level of analgesia.

        3. Population : ages 3 - 17. Sample size 90 patients (30 per arm). Group 1: oral ibuprofen
           at 10mg/kg dose and placebo of equal volume; Group 2: oral APAP at 15 mg/kg dose and
           placebo of equal volume; and, Group 3: oral ibuprofen at 10 mg/kg dose and APAP at
           15mg/kg dose.

        4. Location: Urban tertiary care hospital Pediatric ED with 40,000 annual departmental
           visits.

        5. Duration of Enrollment: 1 year from commencement of the study.

      6/7. Patients will be enrolled and randomized upon triage by an assigned nurse dedicated to
      the study into one of three groups by using a blocks-randomization scheme for every 15
      patients maintained by the ED pharmacists.

      8. For patients experiencing breakthrough pain, oral morphine sulfate at 0.2mg/kg will be
      provided.

      Group 1: oral ibuprofen at 10 mg/kg dose and placebo of equal volume;

      Group 2: oral APAP at 15 mg/kg dose and placebo of equal volume; and,

      Group 3: oral ibuprofen at 10 mg/kg dose and APAP at 15mg/kg dose. Medications including
      placebo will be given via prefilled syringes of identical volume, color and flavor. Level of
      analgesia will be assessed at times 0 and 60 minutes from administration of medication(s).

      All enrolled patients, health care practitioners, and research associates will be blinded to
      the study medication(s) given and to the allocation sequence. Pharmacist(s) who are aware of
      the study medication(s) will not enroll patients. The allocation sequence code will only be
      revealed to the researchers once recruitment, data collection, and data entry are completed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Reduction at 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Pain reduction via Numeric Rating Scale or FACES pain scale at 60 minutes from baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Oral Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral APAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral APAP at 15 mg/kg and placebo of equal volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Oral Ibuprofen at 10 mg/kg dose</description>
    <arm_group_label>Oral Ibuprofen</arm_group_label>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP</intervention_name>
    <description>Oral APAP at 15mg/kg dose</description>
    <arm_group_label>Oral APAP</arm_group_label>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 3-17 years old presenting to the pediatric ED

          -  mild to moderate traumatic/non-traumatic pain (ie, NRS 1-4, FACES)

        Exclusion Criteria:

          -  documented or suspected pregnancy, (2)

          -  parental refusal,

          -  allergies to NSAIDS or APAP

          -  inability to tolerate oral medications or contraindications to oral medication route

          -  received analgesics within 4 hours prior to ED presentation

          -  inability to use pain scales
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonios Likourezos, MA, MPH</last_name>
    <phone>718-283-6896</phone>
    <email>alikourezos@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fromm, MD</last_name>
    <phone>718-283-6391</phone>
    <email>cfromm@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonios Likourezos, MA, MPH</last_name>
      <phone>718-283-6896</phone>
      <email>alikourezos@maimonidesmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Christian Fromm, MD</last_name>
      <phone>718-283-6391</phone>
      <email>cfromm@maimonidesmed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sergey Motov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

